Postmenopausal hormone therapy: A concise guide to therapeutic uses, formulations, risks, and alternatives

Primary Care - Clinics in Office Practice

Volumn 30, Issue 4, 2003, Pages 671-696

  Mitchell, Julie L ^a   Walsh, Judith ^b   Wang Cheng, Rebekah ^a,d   Hardman, Jennifer L ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d St Helena Hosp Prof Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGELICA SINENSIS EXTRACT; BISPHOSPHONIC ACID DERIVATIVE; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESCLIM; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL PLUS NORGESTIMATE; FEMHRT; GESTAGEN; GINSENG EXTRACT; HORMONE; ISOFLAVONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL; NORGESTIMATE; ORTHO PREFEST; PIPERAZINE ESTRONE SULFATE; PRIMROSE OIL; PROGESTERONE; RED CLOVER EXTRACT; SEROTONIN UPTAKE INHIBITOR; TIBOLONE; UNCLASSIFIED DRUG; VENLAFAXINE;

ACNE; ACUPUNCTURE; ADRENAL INSUFFICIENCY; ASTHMA; BLOATING; BREAST CANCER; BRONCHOSPASM; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; DEMENTIA; DIARRHEA; DIZZINESS; DOCTOR PATIENT RELATION; DRUG CONTRAINDICATION; DRUG INDICATION; ENDOMETRIUM CANCER; FATIGUE; FEMALE; FEMALE INFERTILITY; GALLBLADDER DISEASE; GALLSTONE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSOMNIA; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; MOOD; NAUSEA; OSTEOPOROSIS; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SOMNOLENCE; STROKE; SYMPTOM; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VAGINA ATROPHY; VAGINA BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; XEROSTOMIA;

EID: 0347694847     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00093-9     Document Type: Review

References (100)

1. Greendale GA, Wells B, Marcus R, et al. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 2000;160(2):3065-71.
2. Hlatky M, Boothroyd D, Vittinhoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/progestin Replacement Study (HERS) trial. JAMA 2002;287(5):591-7.
3. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-8.
4. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-15.
5. Oldenhave A, Jaszmann LJB, Haspels AA, et al. Impact of climacteric on well-being: a survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-80.
6. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstet Gynecol 1998;92:722-7.
7. Avis NE, Stellato R, Crawford S, et al. Is there an association between menopause status and sexual functioning? Menopause 2000;7:297-309.
8. Hunter MS. Emotional well-being, sexual behaviour and hormone replacement therapy. Maturitas 1990;12:299-314.
9. Fantl JA, Newman DK, Colling J, et al. Urinary incontinence in adults: acute and chronic management. Clinical Practice Guideline, No. 2. Update, AHCPR Publication No. 96-0682. Rockville (MD): Public Health Service, Agency for Health Care Policy and Research; 1996.
10. Dennerstein L. Well being, symptoms and the menopausal transition. Maturitas 1996;23:147-57.
11. Matthews KA, Kuller LH, Wing RR, et al. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-8.
12. Woods NF, Mitchell ES, Adams C. Memory functioning among midlife women: observations from the Seattle midlife women's health study. Menopause 2000;7:257-65.
13. Woods NF, Mitchell ES. Pathways to depressed mood for midlife women: observations from the Seattle midlife women's health study. Res Nurs Health 1997;20:119-29.
14. MacLennan A, Lester A, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001;4:58-74.
15. Bellantoni MF, Harman SM, Cullins VE, et al. Transdermal estradiol with oral progestin: biological and clinical effects in younger and older postmenopausal women. J Gerontol 1991;46(6):M216-22.
16. Geola FL, Frumar AM, Tataryn IV, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980;51:620-5.
17. Molander U, Milsom I, Ekelund MI, et al. Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. Maturitas 1990;12(2):113-20.
18. Carlstrom K, Karlgren E, Furuhjelm M, et al. Effects of intravaginal oestrogen treatment upon the vaginal absorption of conjugated equine oestrogens. Maturitas 1982:4:277-83.
19. Deutsch S, Ossawski R, Benjamin I. Comparison between degree of systemic absorption or vaginally and orally administered estrogens at different dose levels in postmenopausal women. Am J Obstet Gynecol 1981;139:967-8.
20. Tourgeman DE, Gentzchein E, Stanczyk FZ, et al. Serum and tissue hormone levels of vaginally and orally administered estradiol. Am J Obstet Gynecol 1999;180:1480-3.
21. Nachtigall L. Use of low-dose Premarin, Estrace and Estring vaginally. Obstet Gynecol Surv 1998;53:S62-5.
22. Strickler R, Stovall DW, Merritt D, et al. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 2000;96:359-65.
23. Wiklund I, Karlberg J. Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824-30.
24. Myers LS, Dixen J, Morrissette D, et al. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990;70(4):1124-31.
25. McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999;131:605-16.
26. Dennerstein L, Burrows GD, Wood C, et al. Hormones and sexuality: effect of estrogen and progestogen. Obstet Gynecol 1980;56(3):316-22.
27. Sarrel P. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. J Women Health Gender-Based Med 2000;9(Suppl 1):S25-32.
28. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:336-43.
29. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophroectomy. N Engl J Med 2000;343:682-8.
30. Fantl J, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994;83:12-8.
31. Grady D, Brown JS, Vittinghof E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001;97:116-20.
32. Ditkoff EC. Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-5.
33. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997;22:189-212.
34. de Novaes Soares C, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Arch Gen Psychiat 2001:58:529-34.
35. Schmidt PJ, Nieman L, Danaceau, MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183:414-20.
36. Nevitt MC, Felson DT, Williams EN, et al. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: the Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001;44(4):811-8.
37. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54.
38. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285(22):2891-7.
39. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/progestin Replacement Study (HERS). Am J Med 2001;110:442-50.
40. Hulley S, Furberg C. Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
41. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
42. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289:2525-33.
43. Grodstein F, Martinez ME, Platz EA. et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128(9):705-12.
44. Paganini-Hill A, Estrogen replacement therapy and colorectal cancer risk in elderly women. Dis Colon Rectum 1999;42(10):1300-5.
45. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753-6.
46. Brown JS, Vittinghoff E, Kanaya AM, et al. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol 2001;98:1045-52.
47. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933.
48. Psaty BM, Hackbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogen and progestin in postmenopausal women, Arch Intern Med 1994;154:1333.
49. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20(1):47-63.
50. Barrett-Connor E, Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115(6):455-6.
51. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997:315:149-53.
52. Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, et al. Hormone replacement therapy and incidence of acute myocardial infarction: a population-based nested case-control study. Circulation 2000;101(22):2572-8.
53. Johannes CB, Crawford SL, Posner JG, et al. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 1994:140:439-52.
54. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990;336:542-5.
55. Coronary Drug Project Research Group. Influence of adherence to treatment and the response of cholesterol on mortality in the Coronary Drug Project, N Engl J Med 1980;303:1033-41.
56. Herrington DM, Reboussin DM, Brosnihan B, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
57. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280(7):605-13.
58. Schulman SP, Thiemann DR, Ouyang P, et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 2002;39:231-7.
59. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
60. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative Observational Study. JAMA 2002;288:980-7.
61. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
62. Nawaz H, Katz DL. American College of Preventive Medicine Practice Policy Statement: perimenopausal and postmenopausal hormone replacement therapy. Am J Prev Med 1999;17(3):250-4.
63. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:366-8.
64. Wassertheil-Smoller S. Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84.
65. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
66. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638.
67. Writing Group for the PEPI Trial. Effects of estrogen of estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273(3):199-208.
68. Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): a randomized controlled trial. JAMA 1996:276(17):1397-403.
69. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998;279:688-95.
70. LeBlanc ES, Janowsky J, Chan BKS, et al. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001;285:1489-99.
71. Hogervorst E, Williams J, Budge M, et al. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neurology 2000;101:485-512.
72. Shumaker SA, Legault C, Rapp SR. et al. Estrogen plus the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. A randomized controlled trial. JAMA 2003;289:2651-62.
73. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study. A randomized controlled trial. JAMA 2003;289:2663-72.
74. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000;283:1007-15.
75. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy. The Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9.
76. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85(2):304-13.
77. Chu J, Schweid AI, Weiss NS. Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. Am J Obstet Gynecol 1982;143(5):569-73.
78. Lethaby A, Farquhar C, Sarkis A, et al. Hormone replacement therapy in post-menopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2000;181(2):CD000402.
79. Schairer C, Ludin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
80. Stomper PC, D'Souza DJ, DiNitto PA, et al. Analysis of parenchymal density on mammograms in 1353 women 25-79 years old. Am J Radiol 1996;167(5):1261-5.
81. Laya MB, Larson EB, Taplin SH, et al. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1996;88(10):643-9.
82. Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of mammographic screening. Lancet 2000;355(9200):270-4.
83. Rodriquez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of women. JAMA 2001;285:1460-5.
84. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41.
85. Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348(9033):981-3.
86. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348(9033):983-7.
87. Miller J, Chan BKS, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 2002;136:680-90.
88. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132(9):689-96.
89. Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84(6):961-7.
90. Hoibraaten E, Mowinckel MC, de Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115(2):415-20.
91. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001;285(7):906-13.
92. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83:5-11.
93. Uhler ML, Marks JW, Judd HL. Estrogen replacement therapy and gallbladder disease in postmenopausal women. Menopause 2000;7:162-7.
94. Simon JA, Hunninghake DB, Agarwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2001;135(7):493-501.
95. Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991;100(2):482-8.
96. Pripp U, Hall G, Csemiczky C, et al. A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. J Hyperten 1999;17(10):1379-86.
97. Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma: a prospective cohort study. Am J Respir Crit Care Med 1995;152(4 Pt 1):1183-8.
98. Lange P, Parner J, Prescott E, et al. Exogenous female sex steroid hormones and risk of asthma and asthma-like symptoms: a cross sectional study of the general population. Thorax 2001;56(8):613-6.
99. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994;170(5 Pt 1):1213-23.
100. Grady D. A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA 2002;287:2130-7.